NAL ER
NAL ER is a pharmaceutical drug with 6 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
4 of 4 finished
0.0%
0 ended early
2
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
NAL ER IPF Respiratory Function and Safety Study
Refractory Chronic Cough Improvement Via NAL ER (RIVER)
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants
Cough Reduction in IPF With Nalbuphine ER
Clinical Trials (6)
NAL ER IPF Respiratory Function and Safety Study
Refractory Chronic Cough Improvement Via NAL ER (RIVER)
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants
Cough Reduction in IPF With Nalbuphine ER
A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6